An Australian first in chemotherapy protocols
A major Cancer Institute initiative will capture clinical variation in chemotherapy treatment across NSW.
In an Australian first, the Cancer Institute NSW will link the
evidence-based eviQ chemotherapy
protocols to individual patient's treatment information. This
will enable the production of groundbreaking data that will capture
clinical variation.
eviQ is currently used in all Australian states, territories and
more than 981 cities worldwide.
However, there is currently no way to easily track all the
treatments a patient may have received and monitor how these
treatments directly relate to their outcomes.
Work is now underway to manage chemotherapy data across NSW
oncology clinics with vendors of the oncology management
information systems (OMISs) to lay the foundation for standardised
reporting.
This will relieve individual health professionals from sourcing
protocols from eviQ and manually entering relevant data into their
systems. Instead, all existing eviQ protocols will be directly
accessible from the OMISs.
The protocols will be codified to capture chemotherapy treatment
across NSW clinical areas, and collect information about how each
protocol is used.
The monthly reports from the OMISs will also highlight
opportunities to validate the drug dosing and scheduling of
chemotherapy protocols. This information will complement the
clinical trial data to provide a realistic view of the use and
effectiveness of treatments within the general population.
The project reflects the potential of the merge between the NSW
Central Cancer Registry, which collects demographic and disease
information, and the Clinical Cancer Registry, which collects
treatment information, and exciting possibilities of linking this
information to other data sources.
This project will enhance the already comprehensive registry
database in a way that is not available elsewhere in the
country.
It is an exciting time, with work also underway to investigate
the feasibility of data collection from the private sector, and
those sites currently with no OMIS.
Top of page
